1 When can we stop wearing masks? Agent-based modeling to identify when vaccine 2 coverage makes nonpharmaceutical interventions for reducing SARS-CoV-2 infections 3 redundant in indoor gatherings 4 5 **Authors:** Trevor S. Farthing¹ & Cristina Lanzas^{1*} 6 ¹North Carolina State University, Raleigh, North Carolina, USA 7 *Correspondence to Cristina Lanzas (Mailing Address: 1051 William Moore Dr., RB410, 8 Raleigh, NC 27606 | Email: clanzas@ncsu.edu | Phone: 919-513-6202) 9 10 **Declarations of Interest:** None 11 12 **Abstract:** As vaccination efforts to combat the COVID-19 pandemic are ramping up worldwide, 13 there are rising concerns that individuals will begin to eschew nonpharmaceutical interventions 14 for preventing SARS-CoV-2 transmission and attempt to return to pre-pandemic normalcy 15 before vaccine coverage levels effectively mitigate transmission risk. In the U.S.A., some 16 governing bodies have already weakened or repealed guidelines for nonpharmaceutical 17 intervention use, despite a recent spike in national COVID-19 cases and majority population of 18 unvaccinated individuals. Recent modeling suggests that repealing nonpharmaceutical 19 intervention guidelines too early into vaccine rollouts will lead to localized increases in COVID-20 19 cases, but the magnitude of nonpharmaceutical intervention effects on individual-level SARS-21 CoV-2 infection risk in fully- and partially-vaccinated populations is unclear. We use a 22 previously-published agent-based model to simulate SARS-CoV-2 transmission in indoor 23 gatherings of varying durations, population densities, and vaccination coverage levels. By 24 simulating nonpharmaceutical interventions in some gatherings but not others, we were able to 25 quantify the difference in SARS-CoV-2 infection risk when nonpharmaceutical interventions

were used, relative to scenarios with no nonpharmaceutical interventions. We found that nonpharmaceutical interventions will often reduce secondary attack rates, especially during brief interactions, and therefore there is no definitive vaccination coverage level that makes nonpharmaceutical interventions completely redundant. However, the reduction effect on absolute SARS-CoV-2 infection risk conferred by nonpharmaceutical interventions is likely proportional to COVID-19 prevalence. Therefore, if COVID-19 prevalence decreases in the future, nonpharmaceutical interventions will likely still confer protective effects but potential benefits may be small enough to remain within "effectively negligible" risk thresholds.

Keywords: agent-based model, COVID-19, indoor transmission, nonpharmaceutical interventions, SARS-CoV-2, vaccine

Introduction

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

Global vaccine rollout to combat the Coronavirus Disease 2019 (COVID-19) pandemic is well underway, with at least different seven vaccines approved for distribution by different countries (WHO 2021). In the U.S.A., where three vaccines have been approved for distribution (CDC 2021a), 24.8% of the population has been fully vaccinated against COVID-19 as of April 17th 2021 (CDC 2021b). Despite ongoing vaccine rollouts, as of April 17th 2021, there is an indication that COVID-19 cases are surging in some U.S. states (NY Times 2021). In spite of rising case numbers, several U.S. states have recently rescinded, or allowed to expire, policies mandating use of nonpharmaceutical intervention in public spaces, with seemingly no intention of reinstating them in the near future (State of Iowa 2021; State of Mississippi 2021; State of Texas 2021). Population-level epidemiological models of vaccine rollout effects on COVID-19 transmission suggest that discontinuing nonpharmaceutical intervention use early into the vaccination effort leads to a subsequent surge in COVID-19 cases and related hospitalizations and deaths (Gozzi et al. 2021; Moore et al. 2021). The magnitude of nonpharmaceutical intervention effects on individual-level SARS-CoV-2 infection risk in fully- and partially-vaccinated populations is unclear. This information is crucial for identifying vaccination levels at which it would be appropriate to scale-back guidelines for nonpharmaceutical interventions, as it would allow governing bodies to base policies on concrete risk estimates. The United States Centers for Disease Control and Prevention (CDC) has updated guidelines on safe gathering protocols, recommending that groups of fully-vaccinated people can now safely interact amongst themselves, or with small groups of unvaccinated people at low risk for developing severe COVID-19, without utilizing any nonpharmaceutical Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

transmission interventions (e.g., face coverings, 2-m social distancing, etc.) (CDC 2021c). However, the guidelines also recommend to continue avoiding medium to large gatherings, and the use of nonpharmaceutical interventions in public and when gathering with unvaccinated individuals. This caution stems from the incomplete knowledge of vaccine effectiveness across different populations, their effects on transmission, and the potential change on vaccine effectiveness caused by the emergence of new SARS-Cov-2 variants. The problem with citing vaccination efforts as a justification for discontinuing nonpharmaceutical interventions is twofold. First and foremost, the majority of the U.S. population is not yet fully vaccinated (CDC 2021b), and therefore presumably has little-to-no immunity from SARS-CoV-2 infections. Secondly, while there is growing evidence that these vaccines reduce SARS-CoV-2 infection risk in addition to COVID-19 incidence, vaccines may not confer complete immunity or block transmission (Hall et al. 2021; Lipsitch & Kahn 2021; Yellen et al. 2021). Data suggest that the BNT162b2 mRNA vaccine (i.e., the vaccine developed by Pfizer-BioNtech) may be $\approx 72\%$ effective at preventing laboratory-confirmed SARS-CoV-2 infections after a single dose, and $\approx 86-92\%$ two weeks following the second dose (Hall et al. 2021; Yellen et al. 2021). Furthermore, this vaccine may reduce viral loads, a potential proxy for infectiousness, in infected individuals by 3-4 times (Levine-Tiefenbrun et al. 2021). Less information is available on the ability of the other two vaccines approved for U.S. distribution to reduce SARS-CoV-2 infections, but Lipsitch & Kahn (2021) do estimate that mRNA-1273 (i.e., the vaccine developed by Moderna and NIAID) can reduce individual-level infection risk by at least 61% following the first dose. Despite potentially-high infection-reduction efficacies, without vaccines that confer complete immunity from infection or prevent transmission from infectious individuals, it will be difficult to halt SARS-CoV-2 circulation in the population

through vaccination efforts alone (Gozzi et al. 2021; Moore et al. 2021). Considering that most people also have yet to be fully vaccinated, guidelines that advocate phasing out nonpharmaceutical interventions during interpersonal interactions may be premature at this time.

In Farthing & Lanzas (2021), we described an agent-based model (ABM) for simulating indoor respiratory pathogen transmission. We previously used this model to quantify effects of nonpharmaceutical interventions on reducing SARS-CoV-2 transmission risk during an indoor superspreading event (Farthing & Lanzas 2021). Here, we use it to simulate SARS-CoV-2 transmission in indoor gatherings of varying durations, population densities, and proportional vaccination coverage. By simulating nonpharmaceutical interventions in some gatherings but not others, we were able to quantify the difference in SARS-CoV-2 infection risk when nonpharmaceutical interventions were used in conjunction with vaccination efforts, relative to scenarios with no nonpharmaceutical interventions. Using these data, we demonstrate how interested parties can easily estimate the potential reduction in SARS-CoV-2 infection risk attributable to nonpharmaceutical interventions, and try to answer the question: "at what point during vaccine rollout are gatherings without non-pharmaceutical measures safe?"

Methods

We used the ABM we first described in Farthing & Lanzas (2021) to simulate the effect of increasing vaccination coverage and nonpharmaceutical interventions on SARS-CoV-2 transmission risk during indoor gatherings. The simulation input levels and parameter values we used are given in Table 1. We made the assumptions that any infectious individuals at gatherings would be asymptomatic because symptomatic people would consciously decide to stay away, and that no one with partial immunity exists within the group of attendees. Vaccinated people

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

had a fixed probability of becoming completely immune to SARS-CoV-2 infection (Table 1), and those that did not become immune remained susceptible to infection (i.e, 'all-or-nothing' vaccine). Finally, we only simulated use of cloth face coverings, rather than notably moreeffective masks like N95s, because we make the assumption that the majority of Americans have ready access to, and are more-likely to use cloth masks. All simulations were carried out within the open-source modeling software, NetLogo (Ver. 6. 1. 1 – Wilensky 1999). We executed a factorial simulation run in the NetLogo BehaviorSpace using our specified input levels, and ran 200 simulations replicates of each parameter set combination when the nonpharmaceutical interventions were included and when they were not. We ran these factorial combination sets separately in order to save computation time as there were two inputs (i.e., mask efficacy, attempted social distance) that only changed when nonpharmaceutical interventions were simulated. We ultimately produced 1,612,800 simulations without nonpharmaceutical interventions, and 9,676,800 including them (i.e., 11,289,600 total simulations). We recorded the number of susceptible individuals infected in each simulation, and aggregated this information into a single data set prior to analysis. We reported the mean probability of observing ≥ 1 successful infection event(s) and mean secondary attack rates in indoor gatherings when an asymptomatic person was also in attendance across factorial combinations of "between-group comparison" variables (Table 1). Secondary attack rates here were calculated by dividing the number of people that were infected at the gathering by the number of "healthy" people at the start of the gathering, and can also be considered to be the individual-level probability of a previously healthy attendee being infected at the gathering. To assess the difference between protection conferred by the simultaneous deployment of pharmaceutical and nonpharmaceutical interventions, versus use of only

nonpharmaceutical interventions, we first smoothed the observed mean secondary attack rates (μ) by fitting them to a beta regression model with a fixed unknown precision parameter, ϕ using a logit link function to map (0,1) values (Ferrari & Cribari-Neto 2004). The specific model is given by:

133
$$ln\left(\frac{\mu}{1-\mu}\right)(\phi) = (\phi) \beta_0 + \beta_1(Gathering \ duration) + \beta_2(Intervention \ level) +$$
134
$$\beta_3(Vaccine \ coverage) + \beta_4(Vaccine \ efficacy) + \beta_5(Vaccine \ coverage * Vaccine \ efficacy),$$

135 (1)

where "Intervention level" is a categorical variable containing the following mutually-exclusive levels: "cloth face masks & vaccination," "cloth face masks & 2-m social distancing & vaccination," and "vaccination only." Additionally, "Vaccine efficacy" here refers to the ability of vaccines to induce complete immunity to infection. "Vaccine coverage" and "Vaccine efficacy" are given in terms of decimal percent, not percentage points (e.g., 0.1, not 10%).

Because beta regression models assume all dependent variable values fall between 0 and 1, we used the data transformation procedure described by (Cribari-Neto & Zeiles, 2010) to reconstruct our proportion data without these extremities prior to model fitting. We used the pseudo-R² calculation procedure given by Ferrari & Cribari-Neto (2004) to assess the goodness of fit for our regression model.

After fitting our data, we used the regression model to predict the mean secondary attack rates during a 60-minute gathering with a single asymptomatic person in attendance across the complete factorial combination of covariate inputs described in Table 2. We report the difference between predicted values when all interventions (i.e., cloth face masks & 2-m social distancing & vaccination) are utilized, and predicted values assuming vaccinations are the only interventions. All analyses and plotting were carried out using functions from the "betareg"

(Ferrari & Cribari-Neto 2004) and "ggplot2" (v. 3.3.2, Wickham 2016) R packages, respectively, in RStudio (v. 1.1.463, RStudio Team, Boston, MA) (RStudio Team 2018) running R (v. 3.6.2, R Foundation for Statistical Computing, Vienna, Austria) (R Core Team 2020).

Results & Discussion

We found that the probability of ≥ 1 successful transmission event generally increased with population density (Fig. 1). This is unsurprising, as SARS-CoV-2 transmission in this ABM is highly sensitive to within-room population density (Farthing & Lanzas 2021). We observed that at low population densities and/or short-duration gatherings, the use of nonpharmaceutical interventions can significantly reduce the probability of successful transmission. Furthermore, it is clear that at low population densities, 2-m social distancing confers additional protective effects when used in conjunction with cloth face coverings, even during relatively-long duration gatherings. This is consistent with what we observed when we used the same ABM to directly compare the effectiveness of varied nonpharmaceutical interventions to prevent SARS-CoV-2 transmission during a superspreading event (Farthing & Lanzas 2021). We found that cloth face masks alone conferred few protective effects in long-duration gatherings.

The probability of transmission events occurring was unlikely to reach $\approx 0\%$ outside of scenarios with low population density and multiple nonpharmaceutical interventions, or $\geq 95\%$ vaccine coverage and vaccines that were 100% effective at preventing infections. Given that 1) current estimates place SARS-CoV-2 vaccine efficacies against infection between 60-90% (Hall et al. 2021; Lipsitch & Kahn 2021; Yellen et al. 2021), 2) historical precedence suggesting adult populations will fall well short of these high vaccination levels (Applewhite et al. 2020; CDC 2020), and 3) the difficulty government institutions have had enforcing nonpharmaceutical

intervention policies (Jacobs & Ohinmaa 2020; Pedersen & Favero 2020), it is unlikely that these scenarios will be representative of average real-world gatherings. Moreover, in 60-min gathering scenarios, the probability of ≥ 1 successful transmission event occurring is relatively high even when gathering attendees utilize nonpharmaceutical interventions and most are vaccinated.

The probability that ≥1 SARS-CoV-2-positive individual is in attendance at a gathering can be calculated as

$$1 - (1 - p)^n, (2)$$

where p is the local COVID-19 prevalence, and n is the number of people at the gathering (Chande et al. 2020). The prevalence of infectious cases (p) can be highly uncertain because of the variable testing effort across time and space, but it can be estimated by assuming that any SARS-CoV-2-positive individuals are infectious at time of testing and will remain infectious for a given period of time. Additionally, ascertainment bias can be factored in. The probability that a given individual will be infected at a gathering is then

$$(1 - (1 - p)^n)q_i, (3)$$

where q_i is the probability that individual i will be infected given exposure to an asymptomatic individual at the gathering. Effectively, what we report in Fig. 2 are estimates of q_i under different circumstances. Our findings suggest that cloth-based mask use, with or without 2-m social distancing, often does not confer significant protective effects during long-duration gatherings (Fig. 2), we have also shown that implementing these nonpharmaceutical interventions can reduce overall transmission probability (Fig. 1) and secondary attack rates (Fig. 2, Table 3) during brief interactions or gatherings with relatively-few people (e.g., fewer than 10 people, the limit for indoor and/or outdoor social gatherings enforced by some U.S. states (MultiState 2021)). This effectively means that strict guidelines for continued nonpharmaceutical

intervention use will likely help to mitigate SARS-CoV-2 spread, and therefore COVID-19 incidence, for as long as these policies are in effect.

As vaccine coverage increases, the question now becomes "how much elevated risk is acceptable in the absence of nonpharmaceutical interventions?" If we let q_i' denote the probability that individual i will be infected given exposure to an asymptomatic individual at a gathering where no nonpharmaceutical interventions were in place, and q_i^* denote the probability that individual i will be infected given exposure to an asymptomatic individual at a gathering where some level of nonpharmaceutical interventions were in place, then the relative effect of nonpharmaceutical interventions on reducing infection risk is equal to

$$\frac{q_i^*}{q_i'} * 100\%. \tag{4}$$

By quantifying covariate effects in our beta-regression model, we provide interested parties with a formula that can be used to quickly determine generalized q_i' or q_i^* values, without the need for running a large number of simulations. Due to the logit link function we used, the mean secondary attack rates in our ABM simulations (μ) can be predicted using the equation

$$\mu = \frac{e^{\beta_0 + \beta_1 (\text{Gathering duration}) + \beta_2 (\text{Intervention level}) + \beta_3 (\text{Vaccine coverage}) + \beta_4 (\text{Vaccine efficacy}) + \beta_5 (\text{Vaccine coverage*Vaccine efficacy})}{1 + e^{\beta_0 + \beta_1 (\text{Gathering duration}) + \beta_2 (\text{Intervention level}) + \beta_3 (\text{Vaccine coverage}) + \beta_4 (\text{Vaccine efficacy}) + \beta_5 (\text{Vaccine coverage*Vaccine efficacy})}}$$

$$214 (5)$$

(Ferrari & Cribari-Neto 2004). Our regression model had a pseudo-R² of 0.37. Given the number of stochastic processes in our ABM and the variability purposely introduced into simulations (Table 1), we believe the explanatory power of the model is acceptable for our purposes here. Assuming mean population-level vaccine efficacies of 60% and 80%, which we believe are conservative estimates for U.S.-approved vaccine efficacies, our regression model consistently

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

predicts that secondary attack rates decrease by 55-58% when attendees utilize cloth masks and 2-m social distancing, regardless of gathering duration (Fig. 3). However, it is important to reiterate that here we estimate the probability or infection given contact with an infectious individual at a gathering (q_i) and comment on the relative risk difference attributable to intervention use. This should not be confused with the absolute risk of becoming infected at a gathering (see Equation 3). We demonstrate the difference in Figure 4, which is a simplistic example intended to show that even at relatively high COVID-19 prevalence levels, 20 people gathering indoors for 60 minutes have a substantially-lower individual-level risk of SARS-CoV-2 infections than is suggested by q_i alone. Though predicting intervention effects on communitylevel COVID-19 prevalence and infection-related events (e.g., symptom-onset, mortality, or hospitalization) is outside the scope of our model, our simulations do suggest that secondary attack rates are negatively correlated with vaccine coverage. Given that we expect local COVID-19 prevalence to eventually follow similar trends (Gozzi et al. 2021), the relative impact of nonpharmaceutical interventions on infection risk reduction will likely decrease over time as vaccine rollouts continue. In addition to being unable to comment on community-level infection metrics, there are a few other limitations associated with our results that we must acknowledge. Aside from the ABM design limitations outlined in Farthing et al. (2021), we make a number of assumptions in our simulations. Most of these assumptions are directly tied to our parameter space detailed in Table 1, and include such things as: in simulated gatherings only one asymptomatic individual was in attendance, no individuals wear masks with exposure-reduction efficacies > 50% and therefore we are not simulating the use of N95 or similar masks, and there is no simulated forced-air ventilation or infectious individuals that produce superspreader-level of contaminated

aerosols (e.g., 970 quanta (Miller et al. 2020)). Additionally, we do not simulate activity-specific behaviors and individuals in our simulations were unmoving. Finally, we based the infectiousness of asymptomatic individuals on the estimate given by Buonanno et al. (2020) (i.e., 142 quanta/hr), and to relate this estimate to ABM parameters we used the linear model described in Farthing et al. (2021). However, this parameterization procedure may have over-inflated virion transmissibility in certain scenarios because quanta-estimates are room-size specific, and the Farthing et al. (2021) linear model was based on simulations of gatherings within a relatively large room. In short, our results must be viewed through the lens of simulated world parameters and behaviors, and likely will not wholly reflect all variability that may exist in real-world transmission events. This is very common for ABM-based studies however, and we feel that our model is sufficiently accurate to highlight general trends in indoor SARS-CoV-2 transmission and infection risk.

Conclusions

We found that nonpharmaceutical interventions will often reduce secondary attack rates, especially during brief interactions, and therefore there is no definitive vaccination coverage level that makes nonpharmaceutical interventions completely redundant. However, the beneficial effect on absolute SARS-CoV-2 infection risk reduction conferred by nonpharmaceutical interventions used during indoor gatherings is likely proportional to COVID-19 prevalence. Therefore, if U.S. COVID-19 prevalence decreases in the future, nonpharmaceutical interventions will likely still confer protective effects, but any potential benefits may be small enough to remain within "effectively negligible" risk thresholds.

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Acknowledgments This work was partially supported by CDC U01CK000587-01M001 and R35GM134934. **Author Contributions** Trevor Farthing led the model creation, data analysis, and manuscript writing, but both authors conceived the ideas presented herein, contributed to model development and writing efforts, and gave final approval for publication. Cristina Lanzas secured the funding. Data availability We first made our ABM publicly available for download in Farthing et al. (2021). The current iteration can be downloaded from the Lanzas lab's github repository at https://github.com/lanzaslab/droplet-ABM. References 1. Adams WC. Measurement of breathing rate and volume in routinely performed daily activities. 1993. Final Report, Contract No. A033-205. California Air Resources Board, Sacramento, CA, USA. https://ww2.arb.ca.gov/sites/default/files/classic//research/apr/past/a033-205.pdf. 2. Applewhite A, Stancampiano FF, Harris DM, Manaois A, Dimuna J, Glenn J, Heckman MG, Brushaber DE, Sher T, & Valery JR. (2020). A retrospective analysis of gender-based difference in adherence to influenza vaccination during the 2018-2019 season. J Prim Care & Commun Heal 11:1-6. https://doi.org/10.1177%2F2150132720958532.

- 288 3. Buonanno G, Stabile L, & Morawska L. (2020). Estimation of airborne viral emission:
- quanta emission rate of SARS-CoV-2 for infection risk assessment. *Environ Internat*
- 290 141:105794. https://doi.org/10.1016/j.envint.2020.105794.
- 4. Castillo JE, & Weibel JA. (2018). A point sink superposition method for predicting droplet
- interaction effects during vapor-diffusion-driven dropwise condensation in humid air. *Int J*
- 293 *Heat Mass Trans* 118:708-719. https://doi.org/10.1016/j.ijheatmasstransfer.2017.11.045.
- 5. Chande A, Lee S, Harris M, Nguyen Q, Beckett SJ, Hilley T, Andris C, & Weitz JS. (2020).
- Real-time, interactive website for US-county-level COVID-19 event risk assessment. Nat
- 296 Hum Behav. 4:1313-1319. https://doi.org/10.1038/s41562-020-01000-9.
- 297 6. Cribari-Neto F, Zeileis A. (2010). Beta regression in R. J Stat Soft. 34(2):1-24.
- 298 https://doi.org/10.18637/jss.v034.i02.
- 299 7. Das SK, Alam J, Plumari S, Greco V. (2020) Transmission of airborne virus through sneezed
- and coughed droplets. Phys Fluids. 32:097102. https://doi.org/10.1063/5.0022859.
- 301 8. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN,
- Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JP, de Wit E, & Munster VJ.
- 303 (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N
- 304 Engl J Med 2020(382):1564-1567. https://doi.org/10.1056/NEJMc2004973.
- 9. Farthing TS, & Lanzas C. (2021). Assessing the efficacy of interventions to control indoor
- 306 SARS-Cov-2 transmission: an agent-based modeling approach. Preprint available at:
- 307 https://doi.org/10.1101/2021.01.21.21250240.
- 308 10. Ferrari SLP, Cribari-Neto F. (2004). Beta regression for modelling rates and proportions. J
- 309 Appl Stat. 31(7): 799-815. https://doi.org/10.1080/0266476042000214501.

- 310 11. Fryar CD, Kruszon-Moran D, Gu Q, & Ogden CL. (2018). Mean body weight, height, waist
- circumference, and body mass index among adults: United States, 1999–2000 through 2015–
- 312 2016. National Health Statistics Reports, No. 122. United States National Center for Health
- 313 Statistics, Hyattsville, MD, USA. https://stacks.cdc.gov/view/cdc/61430.
- 314 12. Gozzi N, Bajardi P, & Perra N. (2021). The importance of non-pharmaceutical interventions
- during the COVID-19 vaccine rollout. Preprint available at:
- 316 ttps://doi.org/10.1101/2021.01.09.21249480.
- 13. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson
- N, Atti A, Islam J, Karagiannis I, Munro K, Khawam J, The Siren Study Group, Chand MA,
- Brown C, Ramsey ME, Bernal JL, & Hopkins S. (2021). Effectiveness of BNT162b2 mRNA
- vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England,
- multicentre prospective cohort study (the SIREN Study). Preprint available at:
- 322 https://dx.doi.org/10.2139/ssrn.3790399.
- 323 14. Jacobs P, & Ohinmaa AP. (2020). The enforcement of statewide mask wearing mandates to
- prevent COVID-19 in the US: an overview. *F1000Res* 9:1100.
- 325 https://dx.doi.org/10.12688%2Ff1000research.25907.1.
- 326 15. Kwon S-B, Park J, Jang J, Cho Y, Park D-S, Kim C, Bae G-N, & Jang A. (2012). Study on
- 327 the initial velocity distribution of exhaled air from coughing and speaking. *Chemosphere*
- 328 87(11):1260-1264. https://dx.doi.org/10.1016/j.chemosphere.2012.01.032.
- 329 16. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Scheiber L, Wolf T, Nadler V,
- Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, & Kishony R. (2021). Decreased SARS-
- CoV-2 viral load following vaccination. Preprint available at:
- 332 https://doi.org/10.1101/2021.02.06.21251283.

- 17. Lipsitch M, & Kahn R. (2021). Interpreting vaccine efficacy trial results for infection and
- transmission. Preprint available at: https://doi.org/10.1101/2021.02.25.21252415.
- 18. Miller SL, Nazaroff WW, Jimenez JL, Boerstra A, Buonanno G, Dancer SJ, Kurnitski J,
- Marr LC, Morawska L, & Noakes C. (2020). Transmission of SARS-CoV-2 by inhalation of
- respiratory aerosol in the Skagit Valley Chorale superspreading event. *Indoor Air* 00:1-10.
- 338 https://doi.org/1010.1111/ina.12751.
- 19. Moore S, Hill EM, Tildesley MJ, Dyson L, & Keeling M. (2021). Vaccination and non-
- pharmaceutical interventions: when can the UK relax about COVID-19. Preprint available at:
- 341 https://doi.org/10.1101/2020.12.27.20248896.
- 342 20. MultiState. (2021). COVID-19 State and Local Policy Dashboard.
- https://www.multistate.us/research/covid/public. [cited 2021 Apr 14].
- 344 21. O'kelly E, Pirog S, Ward J, Clarkson PJ. (2020). Ability of fabric face mask materials to
- filter ultrafine particles at coughing velocity. *BMJ Open* 10(9):e039424.
- 346 http://dx.doi.org/10.1136/bmjopen-2020-039424.
- 22. Pedersen MJ, & Favero N. (2020). Social distancing during the COVID-19 pandemic: who
- are the present and future noncompliers. *Public Admin Rev* 80(5):805-814.
- 349 https://doi.org/10.1111/puar.13240.
- 23. R Core Team. (2020). R: A language and environment for statistical computing. R
- Foundation for Statistical Computing, Vienna, Austria. https://www.R project.org. [cited]
- 352 2021 Mar 26].
- 24. RStudio Team. (2018). RStudio: integrated development Environment for r. RStudio Team,
- Boston, Massachusetts, USA. http://www.rstudio.com. [cited 2021 Mar 2].

- 25. State of Iowa. (2021). Public health proclamation 2021.02.05.
- 356 https://governor.iowa.gov/sites/default/files/documents/Public%20Health%20Proclamation%
- 357 20-%202021.02.05.pdf. [cited 2021 Mar 26].
- 358 26. State of Mississippi. (2021). Executive order No. 1549.
- https://www.sos.ms.gov/content/executiveorders/ExecutiveOrders/1549.pdf [cited 2021 Mar
- 360 26].
- 361 27. State of Texas. (2021). Executive order GA 34.
- https://open.texas.gov/uploads/files/organization/opentexas/EO-GA-34-opening-Texas-
- response-to-COVID-disaster-IMAGE-03-02-2021.pdf [cited 2021 Mar 26].
- 28. The New York Times [NY Times]. (2021). Coronavirus in the U.S.: latest map and case
- 365 count. https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html#states. [cited
- 366 2021 Apr 17].
- 29. United States Centers for Disease Control and Prevention [CDC]. (2020). Flu vaccination
- 368 coverage, United States, 2019-20 influenza season.
- https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm. [cited 2021 Mar 26].
- 370 30. United States Centers for Disease Control and Prevention [CDC]. (2021a). Different
- vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html.
- 372 [cited 2021 Mar 26].
- 373 31. United States Centers for Disease Control and Prevention [CDC]. (2021b). COVID data
- tracker. https://covid.cdc.gov/covid-data-tracker/#vaccinations. [cited 2021 Apr 17].
- 375 32. United States Centers for Disease Control and Prevention [CDC]. (2021c). CDC issues first
- set of guidelines on how fully vaccinated people can visit safely with others.

377 https://www.cdc.gov/media/releases/2021/p0308-vaccinated-guidelines.html. [cited 2021 378 Mar 26]. 379 33. Wickham, H. (2016). ggplot2: elegant graphics for data analysis. Springer-Verlag, New 380 York, USA. https://ggplot2-book.org/. [cited 2021 Mar 26]. 381 34. Wilensky U. NetLogo. (1999). Center for Connected Learning and Computer-Based 382 Modeling, Northwestern University, Evanston, IL. http://ccl.northwestern.edu/netlogo/. 383 [cited 2021 Mar 26]. 384 35. Wölfel R, Corman VM, Guggemos W, Sailmaier M, Zange S, Müller MA, Niemeyer D, 385 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, 386 Zwirglmaier K, Drosten C, & Wendtner C. (2020). Virological assessment hospitalized 387 patients with COVID-2019. Nature 581:465-469. https://doi.org/10.1038/s41586-020-2196-388 х. 389 36. World Health Organization [WHO]. (2021). COVID-19 vaccines. 390 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines. [cited 391 2021 Mar 26]. 392 37. Yelin I, Katz R, Herzel E, Berman-Zilberstein T, Ben-Tov A, Kuint J, Gazit S, Patalon T, 393 Chodick G, & Kishony R. (2021). Associations of the BNT162b2 COVID-19 vaccine 394 effectiveness with patient age and comorbidities. Preprint available at:

https://doi.org/10.1101/2021.03.16.21253686.

395

Tables

Parameter/Model Input	Purpose [¶]	Value(s)	Reference(s)	
Infectiousness parameters				
Droplet count (droplets/expectoration)†	Fixed value	1.42e ⁵	Buonanno et al. 2020, Farthing & Lanzas 2021	
Droplet spread angle – not coughing (°)	Fixed value	63.5	Kwon et al. 2012	
Droplet travel distance – not coughing (m)	Fixed value	0.55 (0.068)‡§	Das et al. 2020	
Vaccine-induced infectiousness reduction (%)	Within-group variation	0, 25, 50, 75	Vaccination may reduce infectiousness of asymptomatic individuals by as much as 75%, but effects are unclear (Levine-Tiefenbrun et al.	
Scenario environment and individu	ual behavior inputs		2021).	
Area (m²)*	Within-group variation	36, 81, 225	-	
Expectoration height (m)	Fixed value	1.7	Fryar et al. 2018	
Inhalation rate (m³ air/min)	Fixed value	0.023	Adams 1993	
Maximum people in a single 1-m² patch (people)	Fixed value	2	-	
Number of asymptomatic infectious individuals (people)	Fixed value	1	-	
Scenario virion behavior inputs	Fixed value			
Virion count (virions/mL fluid)	Fixed value	2.35e ⁹	Wölfel et al. 2020	
Virion decay rate (%/min)	Fixed value	1.05	van Doremalen et al. 2020	

Virion infection risk (%/inhaled virion)	Fixed value	6.24	Farthing & Lanzas 2021
Scenario airflow inputs			
Diffusion rate (m³/min)	Fixed value	1.5e ⁻³	Castillo & Weibel 2018
Forced airflow	Fixed value	off	-
Scenario intervention inputs			
Seemoto intervention inputs	Between-group comparison:	 Mask use (10% exposure-reduction efficacy), 2m attempted social distancing Mask use (25% exposure-reduction efficacy), 2m attempted social distancing Mask use (50% exposure-reduction efficacy), 2m 	
Nonpharmaceutical	intervention combinations Within-group variation: mask efficacy	 attempted social distancing Mask use (10% exposure- 	Mask use is intended to represent use of <i>cloth</i> masks to prevent exposure to infectious media.
intervention scenarios			Cloth mask efficacy is highly variable (O'kelly
		 social distancing Mask use (25% exposure- 	et al. 2020).
		reduction efficacy), no attempted	
		social distancing	
		• Mask use (50% exposure-	
		reduction efficacy), no attempted	
		social distancing	
		No nonpharmaceutical	
		interventions	

Gathering duration (min)	Between-group comparison	10, 60	-
Vaccine efficacy for preventing			
infection (%)	Between-group comparison	50, 65, 80, 100	-
Vaccine coverage (%)	Between-group comparison	0:100 by 5	
Population density (people/m²)**	Between-group comparison	0.17, 0.33, 0.67, 1	_

Table 1. Model parameter and scenario-specific input descriptions for transmission simulations.

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

*All simulated worlds were square-shaped. The Purpose column describes why the parameter or input was included as it relates to analyses. Specifically, "Fixed value" indicates that values are unchanged across all simulations, and are thus irrelevant for analyses. "Between-group comparison" indicates that levels were used in factorial combinations for data aggregation and reporting. "Within-group variation" indicates that different levels were included to increase the variation in simulation results, and by doing so increase model realism. †Based on linear modeling described in Appendix S2 of Farthing & Lanzas (2021), this value equates to 142 quanta/hr, the average quanta emission rate for asymptomatic people calculated by Buonanno et al. (2020). ‡Standard deviation is given in parentheses. §Das et al. (2020) estimated the average travel distance of a 100-micrometer droplet expelled from a height of 1.7 m at a velocity of 0.5 m/s to be 0.55 m. They also found that the majority of 100-µm droplets will fall 0.55-2.35 m away from the expelling individual, depending on initial velocity, but droplets may settle up to 3.2 m away very rarely. A random draw of 10,000,000 samples from a log-normal distribution parameterized using 1.7-m and 0.2095-m droplet spread distance mean and standard deviation values, respectively, generated a distribution in line with this finding. The standard deviation we use in simulations for non-coughing expectoration is proportionate to the one used in this random draw. **Instead of specifying a fixed number of individuals in simulations, we scaled the simulated population with world size.

Covariate	Value(s)
Gathering duration	60 min
Intervention level	 cloth face masks & 2-m social distancing & vaccination vaccination only
Vaccine coverage	0:1 by 0.1
Vaccine efficacy	0.6, 0.8

Table 2. Covariate values used for prediction in our example.

Coefficient	Estimate	p
Intercept	-3.786 (-3.857, -3.716)	-
φ	28.899 (28.336, 29.462)	-
Gathering duration (min)	0.012 (0.011, 0.012)	< 0.001
Intervention level		
Cloth face masks & 2-m social distancing & vaccination*	0 (0, 0)	-
Cloth face masks & vaccination	0.761 (0.737, 0.785)	< 0.001
Vaccination only	0.889 (0.866, 0.913)	< 0.001
Vaccine coverage	0.783 (0.660, 0.905)	< 0.001
Vaccine efficacy	0.385 (0.297, 0.472)	< 0.001
Vaccine coverage X Vaccine efficacy	-2.652 (-2.816, -2.487)	< 0.001

Table 3. Logit scale estimates associated with 1-unit increases in covariate values given by our beta-regression model. Wald 95% confidence intervals are given in parentheses. *This is the reference level used to establish a baseline for binary dummy variables.

425 Figures




Figure 1. At low population densities and gathering duration limits, nonpharmaceutical

428

429

interventions to prevent infection and elevated vaccination rates consistently decrease the

probability of observing ≥ 1 successful SARS-CoV-2 transmission events in simulations.




Figure 2. Mean secondary attack rates in simulations indicate substantial variability in risk.




Figure 3. Predicted secondary attack rates suggest that the combination of cloth face masks and 2-m social distancing during indoor gatherings of varying durations consistently reduces secondary attack rates by 55-58%. This effect was only modeled for vaccine efficacies of 60% and 80%.




Figure 4. Estimated absolute risk of being infected with SARS-CoV-2 during 60-minute

gatherings of varied sizes. Estimates were obtained by plugging Figure 3 predictions into Equation 3 with fixed COVID-19 prevalence and n values. a) Absolute risk of SARS-CoV-2 transmission given that 10 people attend the gathering. b) Absolute risk of SARS-CoV-2 transmission given that 20 people attend the gathering.